Press release
Non-Small Cell Lung Cancer (NSCLC) Market Overview: Major Segments, Strategic Developments, and Leading Companies
Non-Small Cell Lung Cancer (NSCLC) Market
Projected Market Valuation and Growth Trajectory of the NSCLC Market
The NSCLC market is anticipated to experience rapid growth, reaching a valuation of $70.81 billion by 2030. This corresponds to a robust compound annual growth rate (CAGR) of 11.0% during the forecast period. The expansion is primarily driven by the rising use of targeted therapies and immunotherapies, increased funding for lung cancer diagnostics, the growth of personalized medicine, and the widening network of oncology centers and specialty clinics. Moreover, innovations such as artificial intelligence-based predictive models and enhanced imaging solutions are playing a crucial role in propelling the market forward. Key trends expected to influence this growth include a greater adoption of advanced radiotherapy techniques, growing utilization of laser and photodynamic therapies, expanded early diagnosis and screening programs, and the integration of AI-powered imaging and predictive oncology tools.
Download a free report of the non-small cell lung cancer (nsclc) market report:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Corporations Dominating the NSCLC Market
Several global pharmaceutical and biotechnology companies play a pivotal role in the NSCLC market. Prominent players include Pfizer Inc., F. Hoffmann?La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol?Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Clovis Oncology, Revolution Medicines, Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company Limited, BeiGene Ltd., DualityBio, Gilead Sciences Inc., Mirati Therapeutics Inc., Arcus Biosciences Inc., and NeoImmuneTech.
Strategic Acquisition Strengthening Pfizer's Position in NSCLC
In December 2023, Pfizer Inc., a US-based leader in biopharmaceuticals known for its innovative medicines including small molecules, biologics, and immunotherapies, acquired biotechnology firm Seagen for approximately US$43 billion. This acquisition aims to enhance Pfizer's oncology portfolio, with a particular focus on NSCLC. Seagen's cutting-edge antibody-drug conjugate (ADC) technology is expected to advance the development of next-generation cancer treatments. Seagen, also based in the US, is actively engaged in research and development specifically targeting NSCLC therapies.
View the full non-small cell lung cancer (nsclc) market report:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Trends Positively Influencing the NSCLC Market Growth
The NSCLC market is benefiting from the development of advanced medical devices and diagnostic tools designed to improve treatment personalization and patient outcomes. Companies are focusing on creating portable, cost-effective diagnostic solutions that enhance the accuracy of diagnoses and enable better disease management. For example, the Indian Institute of Technology (IIT) Bombay developed an affordable device in December 2024 aimed at diagnosing and managing tinnitus, which also reflects the broader trend of affordable, precise diagnostic technologies impacting healthcare markets globally. Although this example focuses on tinnitus, the innovation and accessibility principles similarly apply to NSCLC diagnostics, helping to make early and accurate detection more feasible especially in resource-limited settings.
Detailed Segment Breakdown of the NSCLC Market
The NSCLC market can be segmented in several ways to provide a clearer picture of its structure and focus areas:
1) By Type:
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Adenocarcinoma
- Other Types
2) By Therapy:
- Radiotherapy
- Laser Therapy
- Photodynamic Therapy (PDT)
- Other Therapies
3) By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Other Distribution Channels
Each type includes further subcategories, such as:
- Squamous Cell Carcinoma divided into Keratinizing and Non-Keratinizing variants
- Large Cell Carcinoma including Undifferentiated Large Cell Carcinoma and Large Cell Neuroendocrine Carcinoma
- Adenocarcinoma broken down into Invasive Adenocarcinoma and Bronchioloalveolar Carcinoma
- Other Types encompassing Mixed Cell Type Carcinoma and Sarcomatoid Carcinoma
This segmentation highlights the diversity of NSCLC forms and treatment approaches, illustrating the market's complexity and the tailored strategies required to effectively address this disease.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Small Cell Lung Cancer (NSCLC) Market Overview: Major Segments, Strategic Developments, and Leading Companies here
News-ID: 4483114 • Views: …
More Releases from The Business Research Company
Precision Medicine Software Market Overview: Major Segments, Strategic Developme …
The precision medicine software market is gaining significant traction as personalized healthcare becomes increasingly important. With advancements in technology and growing investments in targeted therapies, this sector is poised for substantial expansion. Let's explore the market's projected valuation, key players, main driving forces, current trends, and detailed segments shaping its future.
Forecasted Market Value and Growth of the Precision Medicine Software Market
The precision medicine software market is set to grow…
Segmentation, Major Trends, and Competitive Analysis of the Postpartum Depressio …
The postpartum depression treatment sector is poised for significant expansion as awareness and innovations in maternal mental health continue to advance. With growing attention to personalized care and digital solutions, the market is set to evolve rapidly in the coming years. Let's explore the market size projections, key players, emerging trends, and detailed segmentation driving this vital healthcare field.
Projected Growth Trajectory of the Postpartum Depression Treatment Market
The global postpartum…
Leading Firms Advancing Innovation and Growth in the Postmenopausal Osteoporosis …
The postmenopausal osteoporosis treatment market is on track for significant expansion over the coming years. With advances in therapeutic options and a growing focus on personalized care, this sector is expected to undergo notable changes that will shape how osteoporosis is managed in postmenopausal women by 2030.
Forecasted Growth and Market Size of the Postmenopausal Osteoporosis Treatment Market
The market for postmenopausal osteoporosis treatments is projected to reach a value of…
Global Drivers Analysis: The Rapid Evolution of the Portable Vascular Doppler Ma …
The portable vascular doppler market is on track for significant expansion as advancements in medical technology continue to evolve. Increasing demand for accessible and efficient vascular diagnostic tools is driving interest among healthcare providers, leading to promising growth opportunities in this specialized segment. Let's explore the market's size, key players, emerging trends, and detailed segmentation to better understand the industry's trajectory.
Projected Market Size and Growth Outlook for the Portable Vascular…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
